Given the importance of Cdc20-APC/C in carcinogenesis and the current challenges for developing potent inhibitors, we have utilized the PROTAC platform to design a new targeting approach by promoting the degradation of Cdc20 in cancer cells. This evidence concerns the gene CDC20 and cancer.